Abstract
Angiotensin II (Ang II) type 1 (AT1) receptor is a member of the G protein-coupled receptor superfamily and contains 359 amino acids. AT1 receptor blockers (ARBs, e.g., eprosartan, losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, and azilsartan) have been developed and are available for clinical use, and basic and clinical studies have shown that ARBs are useful for preventing the development of cardiovascular disease. While most ARBs have common molecular structures (biphenyl-tetrazol and imidazole groups), they also show slightly different structures. Some of the benefits conferred by ARBs may not be class-specific effects, and instead may be molecule-specific effects. Their common molecular structures are thought to be responsible for their class effects, whereas their slightly different structures may be important for promoting molecule-specific effects. This review focuses on current evidence regarding the class- and molecule-specific differential effects of ARBs from basic experiments to clinical settings.
Keywords: Angiotensin II type receptor blocker, cardiovascular disease, molecular structures, class-specific effects, molecule-specific effects.
Current Pharmaceutical Design
Title:Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Volume: 19 Issue: 17
Author(s): Satoshi Imaizumi, Shin-ichiro Miura, Eiji Yahiro, Yoshinari Uehara, Issei Komuro and Keijiro Saku
Affiliation:
Keywords: Angiotensin II type receptor blocker, cardiovascular disease, molecular structures, class-specific effects, molecule-specific effects.
Abstract: Angiotensin II (Ang II) type 1 (AT1) receptor is a member of the G protein-coupled receptor superfamily and contains 359 amino acids. AT1 receptor blockers (ARBs, e.g., eprosartan, losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, and azilsartan) have been developed and are available for clinical use, and basic and clinical studies have shown that ARBs are useful for preventing the development of cardiovascular disease. While most ARBs have common molecular structures (biphenyl-tetrazol and imidazole groups), they also show slightly different structures. Some of the benefits conferred by ARBs may not be class-specific effects, and instead may be molecule-specific effects. Their common molecular structures are thought to be responsible for their class effects, whereas their slightly different structures may be important for promoting molecule-specific effects. This review focuses on current evidence regarding the class- and molecule-specific differential effects of ARBs from basic experiments to clinical settings.
Export Options
About this article
Cite this article as:
Imaizumi Satoshi, Miura Shin-ichiro, Yahiro Eiji, Uehara Yoshinari, Komuro Issei and Saku Keijiro, Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170005
DOI https://dx.doi.org/10.2174/1381612811319170005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial from Editor-in-Chief: Amniotic Pulmonary Embolism and the Respiratory System: Management Trends and Future Options
Current Respiratory Medicine Reviews Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews Surgical Complications of Hyperglycaemia
Current Diabetes Reviews Blood-brain Barrier Disruption May Contribute to White Matter Lesions in the Setting of Internal Jugular Venous Stenosis
Current Neurovascular Research Mechanisms of Action of Hypertonic Saline Resuscitation in Severe Sepsis and Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Valves used for Transluminal Implantation in Patients with Aortic Valve Stenosis
Recent Patents on Cardiovascular Drug Discovery Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension
Current Pharmaceutical Biotechnology Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology Synthesis of Novel 3(N,N-dialkylamino)alkyl/phenyl Substituted Thieno [2,3-d]pyrimidinones as H1-Anti-Histaminic and Antimicrobial Agents
Current Bioactive Compounds Overview of Dietary Influences on Atherosclerotic Vascular Disease:Epidemiology and Prevention
Cardiovascular & Hematological Disorders-Drug Targets Purines as Neurotransmitters and Neuromodulators in Blood Vessels
Current Vascular Pharmacology Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Fenofibrate: Metabolic and Pleiotropic Effects
Current Vascular Pharmacology ACE Inhibition of Plant Alkaloids Targeted Approach for Selective Inhibition
Mini-Reviews in Organic Chemistry Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome
Current Neurovascular Research Metabolic Control and Diabetic Retinopathy
Current Diabetes Reviews Therapeutic Use of Calcitriol
Current Vascular Pharmacology Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets